Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimerโs and Parkinsonโs, reported significant third quarter 2025 progress, led by full activation of all 84 sites in its pivotal Phase 3 Alzheimerโs study (NCT06709014) and steady enrollment across the U.S. The company also announced promising biomarker data from its Phase 2/3 Alzheimerโs trial showing strong reductions in inflammation and neurodegeneration, underscoring buntanetapโs disease-modifying potential. Recent achievements include transferring all patents to the new crystal form of buntanetap with IP protection through 2046, publishing supportive pharmacokinetic data, and appointing veteran finance executive Mark Guerin as CFO. โEvery element is now aligned as we move toward our data readoutsโthe final step before an NDA submission,โ said Maria Maccecchini, Ph.D., president and CEO.
To view the full press release, visit https://ibn.fm/rsj63
About Annovis Bio Inc.
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visitย www.annovisbio.com and follow us onย LinkedIn,ย YouTube, andย X.
NOTE TO INVESTORS:ย The latest news and updates relating to ANVS are available in the companyโs newsroom atย https://ibn.fm/ANVS
About InvestorWire
InvestorWireย (โIWโ) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands withinย theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visitย https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:ย https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered byย IBN
